JP2025513855A5 - - Google Patents

Info

Publication number
JP2025513855A5
JP2025513855A5 JP2024560437A JP2024560437A JP2025513855A5 JP 2025513855 A5 JP2025513855 A5 JP 2025513855A5 JP 2024560437 A JP2024560437 A JP 2024560437A JP 2024560437 A JP2024560437 A JP 2024560437A JP 2025513855 A5 JP2025513855 A5 JP 2025513855A5
Authority
JP
Japan
Prior art keywords
cell
pharmaceutical composition
car
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560437A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513855A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065642 external-priority patent/WO2023201238A1/en
Publication of JP2025513855A publication Critical patent/JP2025513855A/ja
Publication of JP2025513855A5 publication Critical patent/JP2025513855A5/ja
Pending legal-status Critical Current

Links

JP2024560437A 2022-04-11 2023-04-11 結合剤及びその使用方法 Pending JP2025513855A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263329664P 2022-04-11 2022-04-11
US63/329,664 2022-04-11
US202263399588P 2022-08-19 2022-08-19
US63/399,588 2022-08-19
PCT/US2023/065642 WO2023201238A1 (en) 2022-04-11 2023-04-11 Binding agents and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025513855A JP2025513855A (ja) 2025-04-30
JP2025513855A5 true JP2025513855A5 (cg-RX-API-DMAC7.html) 2026-04-20

Family

ID=86328509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560437A Pending JP2025513855A (ja) 2022-04-11 2023-04-11 結合剤及びその使用方法

Country Status (7)

Country Link
US (1) US20250333515A1 (cg-RX-API-DMAC7.html)
EP (1) EP4507794A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513855A (cg-RX-API-DMAC7.html)
CN (1) CN119487069A (cg-RX-API-DMAC7.html)
AU (1) AU2023254830A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248167A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023201238A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
HK1008049A1 (en) 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
ATE110108T1 (de) 1987-12-11 1994-09-15 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
JP4383168B2 (ja) 2001-09-12 2009-12-16 ベクトン・ディキンソン・アンド・カンパニー マイクロ針投与デバイスおよび薬物投与デバイス
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
BR112017000939A2 (pt) * 2014-07-21 2017-11-14 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico de cll-1
MA40579A (fr) * 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
EP3250602A1 (en) 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
IL258491B2 (en) 2015-10-16 2023-09-01 Univ Columbia Preparations and methods for inhibiting antigens of a particular lineage
MA43134A (fr) 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc Compositions et méthodes de transduction tumorale
WO2017075537A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
EP3585817A4 (en) 2017-02-22 2020-12-02 Aleta Biotherapeutics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
WO2018156791A1 (en) 2017-02-22 2018-08-30 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
WO2020052543A1 (en) * 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cd33 and constructs thereof
WO2020113063A1 (en) * 2018-11-30 2020-06-04 Aleta Biotherapeutics Inc. Single domain antibodies against cll-1
AU2020338011A1 (en) 2019-08-28 2022-03-10 Vor Biopharma Inc. Compositions and methods for CLL1 modification
AU2021268340A1 (en) * 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
EP4204565A1 (en) 2020-08-28 2023-07-05 Vor Biopharma Inc. Compositions and methods for cll1 modification
EP4204564A1 (en) 2020-08-28 2023-07-05 Vor Biopharma Inc. Compositions and methods for cd123 modification
CN113045658B (zh) * 2020-12-11 2021-12-24 广州百暨基因科技有限公司 抗cll1抗体及其应用

Similar Documents

Publication Publication Date Title
JP2025065142A5 (cg-RX-API-DMAC7.html)
JP2022109953A5 (cg-RX-API-DMAC7.html)
RU2355705C2 (ru) Одноцепочечное цикличное триспецифическое антитело
CN114957475B (zh) 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
JP2021177771A5 (cg-RX-API-DMAC7.html)
JP2023123502A5 (cg-RX-API-DMAC7.html)
JP2023071729A5 (cg-RX-API-DMAC7.html)
JP2023139070A5 (cg-RX-API-DMAC7.html)
JP2025020138A (ja) 免疫細胞活性化のための二重特異性抗体
JP2024177479A (ja) 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトIgM定常領域
JP2020529841A5 (cg-RX-API-DMAC7.html)
JP2019530431A5 (cg-RX-API-DMAC7.html)
JP2019524100A5 (cg-RX-API-DMAC7.html)
US20230212293A1 (en) Pd-1 agonist multimeric binding molecules
JPH05505112A (ja) Aids、arcおよびhiv感染の予防および治療に有用な抗cd4抗体ホモログ
JP2020530777A (ja) 多重特異性抗体とその作製及び使用方法
JP2025508343A5 (cg-RX-API-DMAC7.html)
US20220306760A1 (en) Igm glycovariants
JP2024504728A5 (cg-RX-API-DMAC7.html)
JP2024547218A5 (cg-RX-API-DMAC7.html)
US20210395380A1 (en) Variant antibodies that bind ox40
TW202233694A (zh) 雙特異性抗體
WO2022057875A1 (zh) 靶向4-1bb的单域抗体、其融合蛋白、药物组合物及用途
JP2024544559A5 (cg-RX-API-DMAC7.html)
JP2024507693A5 (cg-RX-API-DMAC7.html)